Antimicrobial Stewardship in Total Joint Arthroplasty: Outcomes of a Collaborative Program Implementation.

Autor:	Hyland SJ; From the Department of Pharmacy Services, Grant Medical Center (OhioHealth) (Hyland, Lopez, Kramer, and Rodgers), the Department of Infectious Diseases, Grant Medical Center (OhioHealth) (Kusumi), the Department of Orthopedics, Grant Medical Center (OhioHealth) (Fada and Lucki), and the Department of Preadmission Testing, Grant Medical Center (OhioHealth) (Mohan), Columbus, OH., Kusumi RK, Lopez LF, Kramer BJ, Fada RA, Mohan VS, Rodgers JKL, Lucki MM
Jazyk:	angličtina
Zdroj:	The Journal of the American Academy of Orthopaedic Surgeons [J Am Acad Orthop Surg] 2022 Oct 15; Vol. 30 (20), pp. e1327-e1336. Date of Electronic Publication: 2022 Jun 30.
DOI:	10.5435/JAAOS-D-21-00722
Abstrakt:	Introduction: Antimicrobial stewardship has been cited as a crucial component of orthopaedic surgical care; however, limited high-quality data exist to guide antibiotic use across the total joint arthroplasty continuum. Antimicrobial stewardship program (ASP) implementation and evaluation is needed in this space. Methods: We pursued a prospective, sequential cohort study of an interprofessional ASP for total joint arthroplasty (TJA) formed in late 2017 at the study institution. Twelve total evidence-based recommendations for protocol change were issued, with 11 accepted and implemented across three project phases spanning March 2018 to December 2019. The primary study outcome was the rate of optimal preoperative intravenous antibiotic selection as assessed for Baseline versus Postintervention time periods. Secondary outcomes included individual antibiotic utilization rates. Descriptive statistics were pursued for institutional surgical site infection (SSI) and postoperative acute kidney injury (AKI) rates across the affected time frame. A cost-benefit analysis of the ASP was estimated from the institutional perspective. Results: The rate of optimal preoperative antibiotic selection increased from 64.9% in the Baseline Period (February 2018, n = 57) to 95.4% in the Postimplementation period (June 2018 to December 2019, n = 1,220) (P < 0.001). The rates of second-line preoperative antibiotics and total perioperative antibiotic exposures decreased. Total SSI and AKI rates in primary elective TJA seemed to decrease from calendar year 2018 to 2019 (deep SSI 1.00% to 0.22%, superficial SSI 0.66% to 0.00%, and AKI 1.97% to 1.03%). The institution realized an estimated $197,050 cost savings per 1000 TJA procedures. Discussion: A comprehensive ASP for TJA was associated with an increased use of optimal preoperative antibiotic selection, decreased total antibiotic exposures, and cost savings, without apparent detriment to SSI or AKI rates. (Copyright © 2022 by the American Academy of Orthopaedic Surgeons.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu